50% improvement in remission with GeneSight-guided care
“Results from this large-scale, double-blind, randomized controlled trial demonstrate the clinically significant utility of this combinatorial pharmacogenomic (PGx) test in improving short- and long-term response and remission rates in depressed adults compared to clinicians’ usual approaches to medication selection.”
Greden J, et al. Combinatorial pharmacogenomics significantly improves response and remission for major depressive disorder: a large, blinded, randomized controlled trial. Poster presentation APA May 2018. Manuscript submitted.
Learn More Download Poster